Ten-year follow-up of two cohorts with an increased risk of variant CJD: donors to individuals who later developed variant CJD and other recipients of these at-risk donors

Vox Sanguinis

Volumn 111, Issue 4, 2016, Pages 325-332

  Checchi, M ^a   Hewitt, P E ^b   Bennett, P ^c   Ward, H J T ^d   Will, R G ^e   Mackenzie, J M ^e   Sinka, K ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b NHS BLOOD AND TRANSPLANT   (United Kingdom)

^c Public Health Directorate   (United Kingdom)

^d HEALTH PROTECTION SCOTLAND   (United Kingdom)

^e UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

blood safety; epidemiology; prions; transfusion transmissible infections

Indexed keywords

ADULT; ARTICLE; BLOOD DONOR; BLOOD SAFETY; BLOOD TRANSFUSION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR INFECTION; CLINICAL ARTICLE; COHORT ANALYSIS; DISEASE FREE SURVIVAL; FOLLOW UP; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NEUROLOGIC DISEASE; PRIORITY JOURNAL; RECIPIENT; RISK ASSESSMENT; VARIANT CREUTZFELDT JAKOB DISEASE; ADVERSE EFFECTS; ASYMPTOMATIC DISEASES; BLOOD; CREUTZFELDT-JAKOB SYNDROME; MALE; TRANSMISSION;

ADULT; ASYMPTOMATIC DISEASES; BLOOD DONORS; BLOOD SAFETY; BLOOD TRANSFUSION; CREUTZFELDT-JAKOB SYNDROME; FOLLOW-UP STUDIES; HUMANS; MALE; RISK ASSESSMENT;

EID: 84992561435     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/vox.12426     Document Type: Article

References (23)

1. Brown P: Creutzfeldt-Jakob disease: reflections on the risk from blood product therapy. Haemophilia 2007; 13(Suppl 5):33–40
2. Will RG, Ironside JW, Zeidler M, et al.: A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 1996; 347:921–925
3. National CJD Research & Surveillance Unit (NCJDRSU): Creutzfeldt-Jakob Disease in the UK. Edinburgh, National CJD Research & Surveillance Unit (NCJDRSU), 2015
4. Wroe SJ, Pal S, Siddique D, et al.: Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case report. Lancet 2006; 368:2061–2067
5. Llewelyn CA, Hewitt PE, Knight RS, et al.: Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 2004; 363:417–421
6. Peden AH, Head MW, Ritchie DL, et al.: Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 2004; 364:527–529
7. Gill ON, Spencer Y, Richard-Loendt A, et al.: Prevalent abnormal prion protein in human appendixes after bovine spongiform encephalopathy epizootic: large scale survey. BMJ 2013; 347:f5675
8. Houston F, McCutcheon S, Goldmann W, et al.: Prion diseases are efficiently transmitted by blood transfusion in sheep. Blood 2008; 112:4739–4745
9. Murayama Y, Masujin K, Imamura M, et al.: Ultrasensitive detection of PrP(Sc) in the cerebrospinal fluid and blood of macaques infected with bovine spongiform encephalopathy prion. J Gen Virol 2014; 95:2576–2588
10. McDowell KL, Nag N, Franco Z, et al.: Blood reference materials from macaques infected with variant Creutzfeldt-Jakob disease agent. Transfusion 2015; 55:405–412
11. Urwin PJ, Mackenzie JM, Llewelyn CA, et al.: Creutzfeldt-Jakob disease and blood transfusion: updated results of the UK Transfusion Medicine Epidemiology Review Study. Vox Sang 2015; 110:310–6
12. Davidson LRR, Llewelyn CA, Mackenzie JM, et al.: Variant CJD and blood transfusion: are there additional cases? Vox Sang 2014; 107:220–225
13. Hewitt PE, Llewelyn CA, Mackenzie J, et al.: Creutzfeldt-Jakob disease and blood transfusion: results of the UK Transfusion Medicine Epidemiological Review study. Vox Sang 2006; 91:221–230
14. Bennett P, Dobra S: Assessing the implications for blood donors if recipients are infected with vCJD. London Standards and Quality Analytical Team, Department of Health, 2005.
15. Bennett P, Dobra S, Gronlund J: The implications for blood donors if a recipient develops variant Creutzfeldt-Jakob disease. ORI 2006; 19:3–13
16. Collinge J: Variant Creutzfeldt-Jakob disease. Lancet 1999; 354:317–323
17. British Committee for Standards in Haematology Blood Transfusion: Task force: guidelines on the clinical use of leucocyte-depleted blood components. Transfus Med 1998; 8:59–71
18. Mead S, Poulter M, Uphill J, et al.: Genetic risk factors for variant Creutzfeldt-Jakob disease: a genome-wide association study. Lancet Neurol 2009; 8:57–66
19. Ironside JW, Bishop MT, Connolly K, et al.: Variant Creutzfeldt-Jakob disease: prion protein genotype analysis of positive appendix tissue samples from a retrospective prevalence study. BMJ 2006; 332:1186–1188
20. Bird SM: Attributable testing for abnormal prion protein, database linkage, and blood-borne vCJD risks. Lancet 2004; 364:1362–1364
21. Bird SM: Written evidence submitted by Professor Sheila M Bird (BTO0011). 2014
22. Gregori L, Yang H, Anderson S: Estimation of variant Creutzfeldt-Jakob disease infectivity titers in human blood. Transfusion 2011; 51:2596–2602
23. Bennett P, Daraktchiev M: Blood-borne transmission of vCJD: re-examination of scenarios. Health Protection Analytical Team, Department of Health, 2011